Galenicum obtains DCP approval for Tigecycline

July 24, 2017

Galenicum completed successfully the European phase of the DCP for Tigecycline at the end of June and has already received the first national marketing authorization for the same in the UK.

The DCP procedure was submitted in Europe on April 27, 2016 for various European countries, including Italy, Spain, Germany, France and the United Kingdom.

Tigecycline is an injectable antibiotic product used to treat skin and soft tissue infections as well as complicated intra-abdominal infections for use in hospitals.

Galenicum has finalized agreements for this product with large multinational companies in the industry. This is Galenicum's second injectable product registration following Caspofungin.